Evidence map›Paper›PMID 39628784›Full record

ReviewEngineering microbiology2024

Recent advances in genome-scale engineering in

Hui Gao, Zhichao Qiu, Xuan Wang, Xiyuan Zhang, Yujia Zhang, Junbiao Dai, Zhuobin Liang

Abstract readReview
In one paragraph

Review in Engineering microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Bacterial live therapeutics for human diseases.Molecular systems biology · 2024
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hui GaoInstitute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Zhichao QiuInstitute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Xuan WangInstitute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Xiyuan ZhangInstitute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Yujia ZhangInstitute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
Junbiao DaiCAS Key Laboratory of Quantitative Engineering Biology, Guangdong Provincial Key Laboratory of Synthetic Genomics and Shenzhen Key Laboratory of Synthetic Genomics. Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen 518055, China.
Zhuobin LiangInstitute of Molecular Physiology, Shenzhen Bay Laboratory, Shenzhen 518132, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Owing to the rapid advancement of genome engineering technologies, the scale of genome engineering has expanded dramatically. Genome editing has progressed from one genomic alteration at a time that could only be employed in few species, to the simultaneous generation of multiple modifications across many genomic loci in numerous species. The development and recent advances in multiplex automated genome engineering (MAGE)-associated technologies and clustered regularly interspaced short palindromic repeats and their associated protein (CRISPR-Cas)-based approaches, together with genome-scale synthesis technologies offer unprecedented opportunities for advancing genome-scale engineering in a broader range. These approaches provide new tools to generate strains with desired phenotypes, understand the complexity of biological systems, and directly evolve a genome with novel features. Here, we review the recent major advances in genome-scale engineering tools developed for

Indexed as

CRISPR-CasE. coliGenome-scale engineeringRecombineering

Identifiers

PMID39628784
PMCPMC11611031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.